Skip to content

Modification to:fastix Thc/Coc Drug Screen Dipstick Test, Fastix Thc/Coc/Met Drug Screen Dipstick Test, Fastix Opi/Met

by Branan Medical Corp.

510(k) K012541

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Special NumberK012541 Date4 Sep 2001ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 22 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

510(k) Number
FDA Product Code
LDJ
Device Class
Class II
Regulation
21 CFR Part 862.3870
Advisory Committee
Clinical Toxicology
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

This device is an enzyme immunoassay for qualitative detection of cannabinoids, opioids, and methadone metabolites in urine specimens. It functions as a rapid, point-of-care test to screen for the presence of these substances, aiding in clinical toxicology assessments.

The Fastix tests are single-use, non-sterile dipstick devices intended for use in clinical laboratory settings or point-of-care environments. They are classified as Class II devices under FDA regulations and require compliance with 21 CFR Part 820 for manufacturing and quality systems. Each test kit includes pre-packaged dipsticks with specific lot numbers for traceability and is authorized under FDA 510(k) clearance (K012541)

Other devices from Branan Medical Corp.

See all devices from Branan Medical Corp. →

Questions

AI-generated answers, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What substances does this test detect, and how quickly can results be obtained?

    This device detects cannabinoids (THC), opioids, and methadone metabolites in urine specimens using an enzyme immunoassay. As a rapid point-of-care test, it is designed for quick screening, though the exact timeframe for results isn’t specified in the data. It’s intended for clinical toxicology assessments in settings like laboratories or point-of-care environments.

  • Are these dipstick tests reusable, and what is their sterility status?

    The Fastix tests are explicitly labeled as single-use, non-sterile dipstick devices. Each test is pre-packaged with a unique lot number for traceability, meaning they cannot be reused after one use. Sterility is not a requirement for this application, as the device is intended for use in clinical toxicology screening.

  • How are these tests supplied, and what should I consider when storing them?

    The tests come in pre-packaged kits, each containing dipsticks with assigned lot numbers for traceability. Storage conditions aren’t detailed in the data, but since they’re non-sterile and single-use, they should be stored in a dry, cool environment (typically 2–25°C) away from direct sunlight or extreme humidity to preserve their integrity until use. Always follow the manufacturer’s instructions for optimal performance.

  • What regulatory pathway was used for FDA clearance, and what does this mean for my facility?

    This device received FDA 510(k) clearance (K012541) under a Special 510(k) classification, determined to be substantially equivalent to a predicate device. The clearance was granted by the FDA’s Clinical Toxicology Advisory Committee in Texas. This means your facility can legally use it for its intended purpose—qualitative detection of cannabinoids, opioids, and methadone metabolites in urine—provided you comply with FDA quality system regulations (21 CFR Part 820).